PAI‐1 and atherothrombosis
Plasminogen activator inhibitor‐1 (PAI‐1) is the major physiologic inhibitor of tissue‐type plasminogen activator in plasma, and is elevated in a variety of clinical situations that are associated with increased risk of ischemic cardiovascular events. Recent insights into the biology of PAI‐1 sugges...
Gespeichert in:
| Veröffentlicht in: | Journal of thrombosis and haemostasis 2005-08, Vol.3 (8), p.1879-1883 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1883 |
|---|---|
| container_issue | 8 |
| container_start_page | 1879 |
| container_title | Journal of thrombosis and haemostasis |
| container_volume | 3 |
| creator | VAUGHAN, D. E. |
| description | Plasminogen activator inhibitor‐1 (PAI‐1) is the major physiologic inhibitor of tissue‐type plasminogen activator in plasma, and is elevated in a variety of clinical situations that are associated with increased risk of ischemic cardiovascular events. Recent insights into the biology of PAI‐1 suggest that it is more than just an innocent bystander in the pathogenesis of ischemic heart disease. Elevated PAI‐1 levels appear to increase the risk of atherothrombotic events and may also promote the progression of vascular disease. The development and testing of specific PAI‐1 antagonists will enable basic and clinical investigators the opportunity to test the hypothesis that vascular PAI‐1 excess promotes the development of intravascular thrombosis and atherosclerosis. |
| doi_str_mv | 10.1111/j.1538-7836.2005.01420.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68483871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68483871</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3670-afbea4b7a1d0f79d9c63c8ae326706ce27d672727a1823447035c72e07202f1c3</originalsourceid><addsrcrecordid>eNqNkMFOwzAMhiMEYmPwBgjtxK3FTtokPXCYJmBDk-AwzlGaplqndh3JJrYbj8Az8iS0dMAV-2BL_v1b_ggZIoTYxM0yxJjJQEjGQwoQh4ARhXB3RPq_g-OfPmGsR868XwJgElM4JT3kCBTiuE8un0fTz_cPHOpVNtSbhXX1ZuHqKq194c_JSa5Lby8OdUBe7u_m40kwe3qYjkezwDAuINB5anWUCo0Z5CLJEsOZkdoy2ky5sVRkXNAmNUrKokgAi42gFgQFmqNhA3Ld-a5d_bq1fqOqwhtblnpl661XXEaSSYGNUHZC42rvnc3V2hWVdnuFoFoyaqnap1ULQLVk1DcZtWtWrw43tmlls7_FA4pGcNsJ3orS7v9trB7nk7ZjX6Wdb9E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68483871</pqid></control><display><type>article</type><title>PAI‐1 and atherothrombosis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>VAUGHAN, D. E.</creator><creatorcontrib>VAUGHAN, D. E.</creatorcontrib><description>Plasminogen activator inhibitor‐1 (PAI‐1) is the major physiologic inhibitor of tissue‐type plasminogen activator in plasma, and is elevated in a variety of clinical situations that are associated with increased risk of ischemic cardiovascular events. Recent insights into the biology of PAI‐1 suggest that it is more than just an innocent bystander in the pathogenesis of ischemic heart disease. Elevated PAI‐1 levels appear to increase the risk of atherothrombotic events and may also promote the progression of vascular disease. The development and testing of specific PAI‐1 antagonists will enable basic and clinical investigators the opportunity to test the hypothesis that vascular PAI‐1 excess promotes the development of intravascular thrombosis and atherosclerosis.</description><identifier>ISSN: 1538-7933</identifier><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1111/j.1538-7836.2005.01420.x</identifier><identifier>PMID: 16102055</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Inc</publisher><subject>Animals ; Atherosclerosis - metabolism ; Atherosclerosis - pathology ; Cardiovascular Diseases - metabolism ; Circadian Rhythm ; Diabetes Mellitus, Type 2 - blood ; fibrinolysis ; Humans ; inhibitor‐1 ; Insulin Resistance ; Ischemia ; plasminogen activator ; Plasminogen Activator Inhibitor 1 - blood ; Plasminogen Activator Inhibitor 1 - physiology ; Protein Structure, Tertiary ; risk factors ; thrombosis ; Thrombosis - metabolism ; Thrombosis - pathology</subject><ispartof>Journal of thrombosis and haemostasis, 2005-08, Vol.3 (8), p.1879-1883</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3670-afbea4b7a1d0f79d9c63c8ae326706ce27d672727a1823447035c72e07202f1c3</citedby><cites>FETCH-LOGICAL-c3670-afbea4b7a1d0f79d9c63c8ae326706ce27d672727a1823447035c72e07202f1c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16102055$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VAUGHAN, D. E.</creatorcontrib><title>PAI‐1 and atherothrombosis</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>Plasminogen activator inhibitor‐1 (PAI‐1) is the major physiologic inhibitor of tissue‐type plasminogen activator in plasma, and is elevated in a variety of clinical situations that are associated with increased risk of ischemic cardiovascular events. Recent insights into the biology of PAI‐1 suggest that it is more than just an innocent bystander in the pathogenesis of ischemic heart disease. Elevated PAI‐1 levels appear to increase the risk of atherothrombotic events and may also promote the progression of vascular disease. The development and testing of specific PAI‐1 antagonists will enable basic and clinical investigators the opportunity to test the hypothesis that vascular PAI‐1 excess promotes the development of intravascular thrombosis and atherosclerosis.</description><subject>Animals</subject><subject>Atherosclerosis - metabolism</subject><subject>Atherosclerosis - pathology</subject><subject>Cardiovascular Diseases - metabolism</subject><subject>Circadian Rhythm</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>fibrinolysis</subject><subject>Humans</subject><subject>inhibitor‐1</subject><subject>Insulin Resistance</subject><subject>Ischemia</subject><subject>plasminogen activator</subject><subject>Plasminogen Activator Inhibitor 1 - blood</subject><subject>Plasminogen Activator Inhibitor 1 - physiology</subject><subject>Protein Structure, Tertiary</subject><subject>risk factors</subject><subject>thrombosis</subject><subject>Thrombosis - metabolism</subject><subject>Thrombosis - pathology</subject><issn>1538-7933</issn><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMFOwzAMhiMEYmPwBgjtxK3FTtokPXCYJmBDk-AwzlGaplqndh3JJrYbj8Az8iS0dMAV-2BL_v1b_ggZIoTYxM0yxJjJQEjGQwoQh4ARhXB3RPq_g-OfPmGsR868XwJgElM4JT3kCBTiuE8un0fTz_cPHOpVNtSbhXX1ZuHqKq194c_JSa5Lby8OdUBe7u_m40kwe3qYjkezwDAuINB5anWUCo0Z5CLJEsOZkdoy2ky5sVRkXNAmNUrKokgAi42gFgQFmqNhA3Ld-a5d_bq1fqOqwhtblnpl661XXEaSSYGNUHZC42rvnc3V2hWVdnuFoFoyaqnap1ULQLVk1DcZtWtWrw43tmlls7_FA4pGcNsJ3orS7v9trB7nk7ZjX6Wdb9E</recordid><startdate>200508</startdate><enddate>200508</enddate><creator>VAUGHAN, D. E.</creator><general>Blackwell Science Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200508</creationdate><title>PAI‐1 and atherothrombosis</title><author>VAUGHAN, D. E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3670-afbea4b7a1d0f79d9c63c8ae326706ce27d672727a1823447035c72e07202f1c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>Atherosclerosis - metabolism</topic><topic>Atherosclerosis - pathology</topic><topic>Cardiovascular Diseases - metabolism</topic><topic>Circadian Rhythm</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>fibrinolysis</topic><topic>Humans</topic><topic>inhibitor‐1</topic><topic>Insulin Resistance</topic><topic>Ischemia</topic><topic>plasminogen activator</topic><topic>Plasminogen Activator Inhibitor 1 - blood</topic><topic>Plasminogen Activator Inhibitor 1 - physiology</topic><topic>Protein Structure, Tertiary</topic><topic>risk factors</topic><topic>thrombosis</topic><topic>Thrombosis - metabolism</topic><topic>Thrombosis - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VAUGHAN, D. E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VAUGHAN, D. E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PAI‐1 and atherothrombosis</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2005-08</date><risdate>2005</risdate><volume>3</volume><issue>8</issue><spage>1879</spage><epage>1883</epage><pages>1879-1883</pages><issn>1538-7933</issn><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract>Plasminogen activator inhibitor‐1 (PAI‐1) is the major physiologic inhibitor of tissue‐type plasminogen activator in plasma, and is elevated in a variety of clinical situations that are associated with increased risk of ischemic cardiovascular events. Recent insights into the biology of PAI‐1 suggest that it is more than just an innocent bystander in the pathogenesis of ischemic heart disease. Elevated PAI‐1 levels appear to increase the risk of atherothrombotic events and may also promote the progression of vascular disease. The development and testing of specific PAI‐1 antagonists will enable basic and clinical investigators the opportunity to test the hypothesis that vascular PAI‐1 excess promotes the development of intravascular thrombosis and atherosclerosis.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Inc</pub><pmid>16102055</pmid><doi>10.1111/j.1538-7836.2005.01420.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1538-7933 |
| ispartof | Journal of thrombosis and haemostasis, 2005-08, Vol.3 (8), p.1879-1883 |
| issn | 1538-7933 1538-7836 1538-7836 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68483871 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Animals Atherosclerosis - metabolism Atherosclerosis - pathology Cardiovascular Diseases - metabolism Circadian Rhythm Diabetes Mellitus, Type 2 - blood fibrinolysis Humans inhibitor‐1 Insulin Resistance Ischemia plasminogen activator Plasminogen Activator Inhibitor 1 - blood Plasminogen Activator Inhibitor 1 - physiology Protein Structure, Tertiary risk factors thrombosis Thrombosis - metabolism Thrombosis - pathology |
| title | PAI‐1 and atherothrombosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T13%3A21%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PAI%E2%80%901%20and%20atherothrombosis&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=VAUGHAN,%20D.%20E.&rft.date=2005-08&rft.volume=3&rft.issue=8&rft.spage=1879&rft.epage=1883&rft.pages=1879-1883&rft.issn=1538-7933&rft.eissn=1538-7836&rft_id=info:doi/10.1111/j.1538-7836.2005.01420.x&rft_dat=%3Cproquest_cross%3E68483871%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68483871&rft_id=info:pmid/16102055&rfr_iscdi=true |